Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)
Pfizer, Inc.’s PFE partner Astellas announced that the Chinese regulatory authority has approved their cancer drug Xtandi. The drug was approved by China National Medical Products Administration (NMPA) on Nov 18 to treat men with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic and had disease …
News story posted on 2019-12-04T12:55:00.0000000Z
